High Biopharma
Transforming Chronic Pain Management
We are a startup biologics company developing a first-in-class,
non-opioid therapy for chronic and neuropathic pain.
Trigeminal Neuralgia is a chronic neuropathic pain condition affecting the face and is widely considered one of the most painful and debilitating diseases.
It is most common in adults over fifty years old and is referred to as the “suicide disease” with approximately 25% of patients experiencing suicide-related thoughts or actions.
Current medications target the symptoms and can cause an array of side effects or only offer modest relief. The severity and persistence of the disease combined with insufficient relief commonly drives patients to opioids.
The addictive nature of opioids and potential abuse has resulted in a global opioid crisis.
Over 100,000 deaths annually are attributed to drug use, with approximately 75% relating to opioids.
Opioids remain powerful pain medications but are primarily prescribed for the treatment of moderate to severe-acute pain.
Long-term use comes with significant risks of addiction and abuse, making them a dangerous treatment for chronic pain.
High Biopharma uses a specialized antibody, known as a biologic pharmaceutical, to target a key pain signaling pathway that causes chronic neurophathic pain. This approach aims to eliminate the cause of the pain at the source rather than masking the symptoms.
Our mission is to provide
durable relief without dependence
Get in Touch
Contact High Biopharma to get in touch, inquire, or explore collaboration opportunities.